The central nervous system contains a family of enzymes known as cholinesterase (ChE), which catalyzes the hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid. This reaction is required for cholinergic neurons to return to their resting state after activation. It is one of many crucial enzymes required for the healthy operation of human nervous systems.
There are two: butyrylcholinesterase (BChE, acylcholine acylhydrolase), also referred to as nonspecific cholinesterase or pseudocholinesterase, and acetylcholinesterase (AChE, acetylcholine hydrolase). While BChE is made in the liver and is mainly found in plasma, AChE is mainly found in the blood on the membranes of red blood cells, at neuromuscular junctions, and in neural synapses. The relative substrate preferences of the two types of cholinesterase are different: AChE hydrolyzes acetylcholine more quickly while BChE hydrolyzes butyrylcholine more quickly.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V78730 | AChE/BChE/MAO-B-IN-4 | AChE/BChE/MAO-B-IN-4 is a 1-indanone analogue and a potent MAO-B inhibitor (antagonist) with IC50 of 0.0359 μM for human MAO-B. | ||
V71628 | AChE/BuChE-IN-4 | 1997158-25-4 | AChE/BuChE-IN-4 (compound 4a) is a multi-target AChE/BuChE inhibitor (antagonist) with oral activity and BBB (blood-brain barrier) permeability. | |
V70698 | AChE/BuChE/MAO-B-IN-1 | 2834758-29-9 | AChE/BuChE/MAO-B-IN-1 is an inhibitor (blocker/antagonist) of human acetylcholinesterase (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B), with IC50 of 4.8 μM and 13.7 μM respectively. | |
V79947 | AChE/BuChE/MAO-B-IN-2 | AChE/BuChE/MAO-B-IN-2 (compound 4b) is a drug with AChE/BuChE inhibitory effect. | ||
V79154 | AChE/MAO-B-IN-4 | AChE/MAO-B-IN-4 (compound 4a) is a selective dual (bifunctional) inhibitor of AChE and MAO-B. | ||
V79015 | AChE/MAO-B-IN-5 | AChE/MAO-B-IN-5 is a dual (bifunctional) inhibitor of AChE and MAO-B. | ||
V77751 | AChE/MAO-B-IN-6 | AChE/MAO-B-IN-6 (compound 3a) is a dual (bifunctional) inhibitor of AChE and h-MAO-B and may be used to inhibit Alzheimer's disease (AD). | ||
V79288 | AChE/MAO-IN-2 | Dual AChE-MAO B-IN-5 is an indanone analogue and a potent dual AChE/MAO-B inhibitor (antagonist) with IC50s of 0.0224 and 0.0412 for AChE, MAO-B and MAO-A respectively. | ||
V71671 | AChE/Nrf2 modulator 1 | 2417117-84-9 | AChE/Nrf2 modulator 1 is an orally bioactive acetylcholinesterase (AChE)/nuclear factor erythroid 2-related factor 2 (Nrf2) modulator. | |
V71666 | Aldicarb sulfone-13C2,d3 (aldicarb sulfone 13C2,d3) | 1261170-76-6 | Aldicarb sulfone-13C2,d3 is the 13C (carbon 13)-labeled deuterated form of Aldicarb sulfone. | |
V71662 | Aloveroside A | 1246930-65-3 | Aloveroside A is a triglucosylnaphthalene analogue extracted from ethanolic extract of aloe vera. | |
V71687 | Artanin | 96917-26-9 | Artanin is a coumarin with bioactivity associated with AD/Alzheimer's disease. | |
V71674 | Axillaridine A | 128255-16-3 | Axillaridine A can be extracted from Sarcococcus hougli var. | |
V79320 | BChE-IN-15 | BChE-IN-15 (Compound 6) is a pseudo-irreversible, covalent BChE inhibitor (antagonist) with IC50 of 1.76 nM for hBChE. | ||
V78353 | BChE-IN-16 | BChE-IN-16 (compound 87) is a potent BChE inhibitor (antagonist) with IC50 of 3.8 nM for hBChE. | ||
V71704 | BChE-IN-17 | 2425632-57-9 | BChE-IN-17 (compound 6n) is a potent and specific BChE inhibitor (antagonist) with IC50s of 10.5 nM and 32.5 nM for eqBChE and hBChE, respectively. | |
V78828 | BChE-IN-19 | BChE-IN-19 (Compound 7b) is a para-substituted analogue of indanone with inhibitory effect against butyrylcholinesterase (BChE) (IC50=0.04 μM). | ||
V79380 | BChE-IN-2 | BChE-IN-2 (compound 22) is a potent BChE inhibitor (antagonist) with Ki of 0.099 μM. | ||
V71629 | BChE-IN-20 | 1428439-79-5 | BChE-IN-20 (compound 7c) is a potent and specific inhibitor of BChE with IC50s of 105 nM and 2.3 nM for eqBChE and hBChE, respectively. | |
V78354 | BChE-IN-21 | BChE-IN-21 is a potent BChE inhibitor (antagonist) with IC50 of 0.14±0.02 μM. |